KR20110138416A - 새로운 용도 - Google Patents

새로운 용도 Download PDF

Info

Publication number
KR20110138416A
KR20110138416A KR1020117027762A KR20117027762A KR20110138416A KR 20110138416 A KR20110138416 A KR 20110138416A KR 1020117027762 A KR1020117027762 A KR 1020117027762A KR 20117027762 A KR20117027762 A KR 20117027762A KR 20110138416 A KR20110138416 A KR 20110138416A
Authority
KR
South Korea
Prior art keywords
gal
galactooligosaccharide
glc
inflammatory
inflammatory disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117027762A
Other languages
English (en)
Korean (ko)
Inventor
게오르지오스 쵸르치스
젤레나 뷸레빅
프란체스코 아타나시오
Original Assignee
클라사도 인크, 씨/오 아로세메나 노리에가 앤 콘트레라스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40774842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20110138416(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 클라사도 인크, 씨/오 아로세메나 노리에가 앤 콘트레라스 filed Critical 클라사도 인크, 씨/오 아로세메나 노리에가 앤 콘트레라스
Publication of KR20110138416A publication Critical patent/KR20110138416A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
KR1020117027762A 2009-04-23 2010-04-23 새로운 용도 Ceased KR20110138416A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0906983.2A GB0906983D0 (en) 2009-04-23 2009-04-23 Novel use
GB0906983.2 2009-04-23
GB0920784.6 2009-11-27
GBGB0920784.6A GB0920784D0 (en) 2009-04-23 2009-11-27 Novel use

Publications (1)

Publication Number Publication Date
KR20110138416A true KR20110138416A (ko) 2011-12-27

Family

ID=40774842

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117027762A Ceased KR20110138416A (ko) 2009-04-23 2010-04-23 새로운 용도

Country Status (25)

Country Link
US (1) US20120058972A1 (https=)
EP (1) EP2421541B1 (https=)
JP (1) JP2012524770A (https=)
KR (1) KR20110138416A (https=)
CN (1) CN102427818A (https=)
AU (1) AU2010240642B2 (https=)
BR (1) BRPI1015091A2 (https=)
CA (1) CA2759442C (https=)
CY (1) CY1120597T1 (https=)
DK (1) DK2421541T3 (https=)
ES (1) ES2688786T3 (https=)
GB (3) GB0906983D0 (https=)
HU (1) HUE040451T2 (https=)
IL (1) IL215855A0 (https=)
MX (1) MX341308B (https=)
MY (1) MY151104A (https=)
NZ (1) NZ595969A (https=)
PL (1) PL2421541T3 (https=)
PT (1) PT2421541T (https=)
RU (1) RU2530567C2 (https=)
SG (1) SG175313A1 (https=)
TR (1) TR201810868T4 (https=)
UA (1) UA106491C2 (https=)
WO (1) WO2010122344A1 (https=)
ZA (1) ZA201107821B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964234A1 (en) * 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
WO2023132399A1 (ko) * 2022-01-07 2023-07-13 (주)네오크레마 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
CN103716787B (zh) 2012-09-29 2020-06-23 北京三星通信技术研究有限公司 一种支持对家用基站进行验证的方法
CN107158011A (zh) * 2017-05-25 2017-09-15 浙江大学 低聚半乳糖在制备治疗肠道疾病的药物中的用途
US12508273B2 (en) 2019-05-15 2025-12-30 N.V. Nutricia Beta-1,3′-galactosyllactose for the treatment of gut barrier function diseases
US20240277739A1 (en) * 2021-07-01 2024-08-22 N.V. Nutricia Nutritonal compositions for gut barrier function
GB2619977A (en) * 2022-06-24 2023-12-27 Clasado Res Services Limited Compositions and uses thereof
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0315266D0 (en) * 2003-06-30 2003-08-06 Clasado Inc Novel galactooligosaccharide composition and the preparation thereof
ATE360682T1 (de) * 2003-06-30 2007-05-15 Clasado Inc Neue galactooligosaccharidzusammensetzung und herstellung davon
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
EP1887017A1 (en) * 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
GB0809921D0 (en) 2008-05-30 2008-07-09 Clasado Inc Product and process therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964234A1 (en) * 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
WO2023132399A1 (ko) * 2022-01-07 2023-07-13 (주)네오크레마 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
PT2421541T (pt) 2018-10-15
RU2011147390A (ru) 2013-05-27
SG175313A1 (en) 2011-11-28
MX2011011159A (es) 2011-11-07
CN102427818A (zh) 2012-04-25
IL215855A0 (en) 2012-01-31
WO2010122344A1 (en) 2010-10-28
GB2482817B (en) 2014-02-26
MX341308B (es) 2016-08-12
CY1120597T1 (el) 2019-12-11
CA2759442A1 (en) 2010-10-28
NZ595969A (en) 2013-03-28
DK2421541T3 (en) 2018-09-24
EP2421541B1 (en) 2018-07-11
JP2012524770A (ja) 2012-10-18
BRPI1015091A2 (pt) 2016-04-26
TR201810868T4 (tr) 2018-08-27
AU2010240642A1 (en) 2011-11-10
ZA201107821B (en) 2012-07-25
GB201120030D0 (en) 2012-01-04
US20120058972A1 (en) 2012-03-08
AU2010240642B2 (en) 2013-03-14
HUE040451T2 (hu) 2019-03-28
MY151104A (en) 2014-04-15
EP2421541A1 (en) 2012-02-29
CA2759442C (en) 2016-01-19
GB2482817A (en) 2012-02-15
GB0906983D0 (en) 2009-06-03
RU2530567C2 (ru) 2014-10-10
UA106491C2 (uk) 2014-09-10
GB0920784D0 (en) 2010-01-13
ES2688786T3 (es) 2018-11-06
PL2421541T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
KR20110138416A (ko) 새로운 용도
US20110082102A1 (en) Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
Newburg et al. Human milk oligosaccharides and synthetic galactosyloligosaccharides contain 3′-, 4-, and 6′-galactosyllactose and attenuate inflammation in human T84, NCM-460, and H4 cells and intestinal tissue ex vivo
Ying et al. Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling
AU2015262214B2 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria
US8425930B2 (en) Prebiotic oligosaccharides
EP4364745A2 (en) Novel lactic acid bacteria and use thereof
CN107771083A (zh) 聚糖治疗剂和治疗方法
Del Fabbro et al. Microbiota-independent immunological effects of non-digestible oligosaccharides in the context of inflammatory bowel diseases
Saba et al. A C-type lectin MGL1/CD301a plays an anti-inflammatory role in murine experimental colitis
KR20180123737A (ko) 박테리아성 히스타민의 산물 및 이의 용도
Ambrogi et al. Bifidobacterial β-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments
Sato et al. An effectiveness study of hyaluronic acid [Hyabest®(J)] in the treatment of osteoarthritis of the knee on the patients in the United States
Morrow et al. Human milk oligosaccharide
Zuurveld et al. Specific human milk oligosaccharides differentially promote Th1 and regulatory responses in a CpG-activated epithelial/immune cell coculture. Biomolecules. 2023; 13 (2): 263. DOI: 10.3390/biom13020263
KR102310175B1 (ko) 프로바이오틱스 및 천연물 혼합물을 포함하는 대장 기능 개선용 조성물
Ambrogi et al. Bifidobacterial ß-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments
CN121843703A (zh) 调节性t细胞的诱导促进剂、自身免疫性疾病的治疗或预防剂、过敏疾病的治疗或预防剂、用于预防自身免疫性疾病的食品组合物、用于预防过敏性疾病的食品组合物、用于改善过敏状态的食品组合物、用于维持健康的免疫功能的食品组合物、自身免疫性疾病或过敏性疾病的治疗或预防方法、及促进调节性t细胞诱导的物质的筛选方法
Stanya et al. 1-s2. 0-S2212877817305239-main. pdfddbriar@ gmail. com
Ambrogi et al. β-Galactosidase-Mediated Production of Galacto-Oligosaccharides: Structural and Preliminary Functional Assessments
Zhao Strain-specific Effects of Bifidobacterium Animalis. Lactis on in Vitro Models of Gastrointestinal Inflammation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140521

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151116

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160526

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151116

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20160526

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160118

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140521

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20160923

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160824

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20160526

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160118

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20151116

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140521